Oragenics, Inc. (OGEN)
OGEN Stock Price Chart
Explore Oragenics, Inc. interactive price chart. Choose custom timeframes to analyze OGEN price movements and trends.
OGEN Company Profile
Discover essential business fundamentals and corporate details for Oragenics, Inc. (OGEN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
25 Feb 2004
Employees
3.00
Website
https://www.oragenics.comCEO
Janet Huffman
Description
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
OGEN Financial Timeline
Browse a chronological timeline of Oragenics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 7 May 2026
Upcoming earnings on 12 Mar 2026
Upcoming earnings on 11 Nov 2025
Earnings released on 8 Aug 2025
EPS came in at -$3.10 .
Stock split effective on 3 Jun 2025
Shares were split 1 : 30 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 9 May 2025
EPS came in at -$3.60 .
Earnings released on 14 Mar 2025
EPS came in at -$0.11 .
Earnings released on 13 Nov 2024
EPS came in at -$0.38 .
Earnings released on 9 Aug 2024
EPS came in at -$0.51 .
Earnings released on 15 May 2024
EPS came in at -$0.70 .
Earnings released on 29 Mar 2024
EPS came in at -$5.48 falling short of the estimated -$3.00 by -82.67%, while revenue for the quarter reached -$37.65K .
Earnings released on 9 Nov 2023
EPS came in at -$0.85 surpassing the estimated -$3.00 by +71.67%, while revenue for the quarter reached $7.47K .
Earnings released on 14 Aug 2023
EPS came in at -$1.51 surpassing the estimated -$3.00 by +49.67%, while revenue for the quarter reached $13.16K .
Earnings released on 12 May 2023
EPS came in at -$1.41 surpassing the estimated -$3.00 by +53.00%.
Earnings released on 29 Mar 2023
EPS came in at -$0.12 surpassing the estimated -$2.40 by +94.94%, while revenue for the quarter reached $131.52K .
Stock split effective on 23 Jan 2023
Shares were split 1 : 60 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Nov 2022
EPS came in at -$1.80 surpassing the estimated -$3.00 by +40.00%, while revenue for the quarter reached $86.05K .
Earnings released on 9 Aug 2022
EPS came in at -$1.80 falling short of the estimated -$1.44 by -25.00%, while revenue for the quarter reached $30.39K .
Earnings released on 13 May 2022
EPS came in at -$2.99 falling short of the estimated -$1.20 by -150.00%, while revenue for the quarter reached $15.08K .
Earnings released on 24 Mar 2022
EPS came in at -$1.20 falling short of the estimated -$0.80 by -50.00%, while revenue for the quarter reached $86.99K .
Earnings released on 15 Nov 2021
EPS came in at -$2.40 falling short of the estimated -$0.00 by -358.11K%.
Earnings released on 16 Aug 2021
EPS came in at -$1.80 falling short of the estimated -$1.44 by -25.00%.
Earnings released on 3 May 2021
EPS came in at -$2.99 falling short of the estimated -$2.69 by -11.11%.
Earnings released on 2 Mar 2021
EPS came in at -$2.99 surpassing the estimated -$3.59 by +16.71%.
Earnings released on 10 Nov 2020
EPS came in at -$4.79 falling short of the estimated -$4.19 by -14.32%.
OGEN Stock Performance
Access detailed OGEN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.